Evaxion Biotech A/S (EVAX) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Evaxion Biotech A/S
Sector
Healthcare
Industry
Biotechnology
Employees
46
First IPO Date
February 05, 2021
Key Executives
| Name | Title | Pay | Year Born |
| Helen Katrina Tayton-Martin | Chief Executive Officer | 428,972 | 1967 |
| Andreas Holm Mattsson | Founder & Chief AI Officer | 364,000 | 1971 |
| Thomas Frederik Schmidt | Chief Financial Officer | 376,000 | 1971 |
| Birgitte Rono | Chief Scientific Officer & COO | 402,000 | 1977 |
| Benjamin Ole Wolthers | Vice President of Clinical Development | 0 | N/A |
Description
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.
